Not available
Quote | SELLAS Life Sciences Group Inc. (NASDAQ:SLS)
Last: | $1.17 |
---|---|
Change Percent: | 5.41% |
Open: | $1.12 |
Close: | $1.11 |
High: | $1.17 |
Low: | $1.12 |
Volume: | 525,443 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | SELLAS Life Sciences Group Inc. (NASDAQ:SLS)
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Received Last Month - -...
Message Board Posts | SELLAS Life Sciences Group Inc. (NASDAQ:SLS)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $SLS News Article - Solaris Discovers New Porphyry Southwest of Warintza Central, with | whytestocks | investorshangout | 04/11/2023 4:30:58 PM |
After that dilution itl double in price, always does | harry crumb | investorshub | 03/03/2023 4:19:41 PM |
Breakout coming, this science could be a game changer | harry crumb | investorshub | 02/16/2023 2:23:43 AM |
Fingers crossed! Still an unknown, to us, | TTsr | investorshub | 02/03/2023 3:29:52 PM |
News coming? Its rippn | harry crumb | investorshub | 02/03/2023 3:17:11 PM |
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
SELLAS Life Sciences Group Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Received Last Month - -...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...